Compare $NVAX vs $PVLA | Chartloom

Compare

$NVAX vs $PVLA

Novavax Inc · Palvella Therapeutics Inc

NVAX

Novavax Inc

PVLA

Palvella Therapeutics Inc

Compare $NVAX vs $PVLA

Comparing Novavax Inc and Palvella Therapeutics Inc

NVAXNovavax Inc

PVLAPalvella Therapeutics Inc

NVAXNovavax Inc

Market cap

$2.10B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

10.28x

Rev growth (TTM)

-61.6%

YTD performance

78.8%

52W performance

43.3%

FCF yield

-2.0%

PVLAPalvella Therapeutics Inc

Market cap

$1.99B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-97.2%

YTD performance

38.4%

52W performance

85.4%

FCF yield

-1.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

NVAX

PVLA

Detailed metrics comparison

NVAX

Novavax Inc

PVLA

Palvella Therapeutics Inc

Market Cap

NVAX$2.10B

PVLA$1.99B

Enterprise Value

NVAX$2.20B

PVLA$1.82B

Price

NVAX$12.75

PVLA$138.77

P/E Ratio

NVAXN/A

PVLAN/A

P/S Ratio

NVAX5.07x

PVLA46.64x

EV/Sales

NVAX5.32x

PVLA0.00x

EV/EBITDA

NVAX4.05x

PVLA0.00x

P/B Ratio

NVAX45.86x

PVLA8.80x

P/FCF Ratio

NVAXN/A

PVLAN/A

EV/FCF

NVAX-51.40x

PVLA-49.96x

PEG Ratio

NVAXN/A

PVLAN/A

Forward P/E (NTM)

NVAXN/A

PVLAN/A

Forward P/S (NTM)

NVAX10.28x

PVLAN/A

Revenue (TTM)

NVAX$414M

PVLA$0

Revenue Growth (YoY)

NVAX-61.6%

PVLA-97.2%

Forward Rev Growth

NVAX-25.1%

PVLA287.4%

Gross Margin (TTM)

NVAX79.2%

PVLA0.0%

Operating Margin (TTM)

NVAX0.0%

PVLA0.0%

EBITDA Margin (TTM)

NVAX-24.0%

PVLA0.0%

Net Margin (TTM)

NVAX-59.9%

PVLA0.0%

FCF Margin (TTM)

NVAX-10.4%

PVLAN/A

Net Income (TTM)

NVAX$-248M

PVLA$-62M

FCF (TTM)

NVAX$-43M

PVLA$-37M

EPS (TTM)

NVAX-$1.51

PVLA-$4.30

ROE (TTM)

NVAX283.1%

PVLA-4784.0%

ROA (TTM)

NVAX-2275.0%

PVLA-3833.0%

ROIC (TTM)

NVAX40.0%

PVLA-4172.0%

Cash

NVAX$191M

PVLA$188M

Debt

NVAX$297M

PVLA$22M

Net Cash/Debt

NVAX$-106M

PVLA$166M

Current Ratio (TTM)

NVAX2.33x

PVLA21.18x

Quick Ratio (TTM)

NVAX2.23x

PVLA21.01x

Debt/Equity (TTM)

NVAX6.07x

PVLA0.10x

Debt/Assets (TTM)

NVAX0.0%

PVLA0.0%

Interest Coverage (TTM)

NVAXN/A

PVLAN/A

Net Debt/EBITDA (TTM)

NVAX0.00x

PVLA0.00x

Beta

NVAX2.81

PVLA-0.19

52W Performance

NVAX43.3%

PVLA85.4%

YTD Performance

NVAX78.8%

PVLA38.4%

% from 52W High

NVAX-4.7%

PVLA-14.0%

% from 52W Low

NVAX105.6%

PVLA110.5%

Asset Turnover (TTM)

NVAX0.38x

PVLA0.76x

FCF Yield (TTM)

NVAX-2.0%

PVLA-1.8%

Earnings Yield (TTM)

NVAX-11.8%

PVLA-3.1%

Dividend Yield (TTM)

NVAXN/A

PVLAN/A

Rule of 40

NVAX-72.0

PVLA-97.2

EV/GP/RG

NVAXN/A

PVLAN/A

Ticker research

View NVAX research View PVLA research

Metric	NVAX Novavax Inc	PVLA Palvella Therapeutics Inc
Market & Valuation
Market Cap	$2.10B	$1.99B
Enterprise Value	$2.20B	$1.82B
Price	$12.75	$138.77
P/E Ratio	N/A	N/A
P/S Ratio	5.07x	46.64x
EV/Sales	5.32x	0.00x
EV/EBITDA	4.05x	0.00x
P/B Ratio	45.86x	8.80x
P/FCF Ratio	N/A	N/A
EV/FCF	-51.40x	-49.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	10.28x	N/A
Revenue & Growth
Revenue (TTM)	$414M	$0
Revenue Growth (YoY)	-61.6%	-97.2%
Forward Rev Growth	-25.1%	287.4%
Profitability
Gross Margin (TTM)	79.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-24.0%	0.0%
Net Margin (TTM)	-59.9%	0.0%
FCF Margin (TTM)	-10.4%	N/A
Net Income (TTM)	$-248M	$-62M
FCF (TTM)	$-43M	$-37M
EPS (TTM)	-$1.51	-$4.30
ROE (TTM)	283.1%	-4784.0%
ROA (TTM)	-2275.0%	-3833.0%
ROIC (TTM)	40.0%	-4172.0%
Financial Health
Cash	$191M	$188M
Debt	$297M	$22M
Net Cash/Debt	$-106M	$166M
Current Ratio (TTM)	2.33x	21.18x
Quick Ratio (TTM)	2.23x	21.01x
Debt/Equity (TTM)	6.07x	0.10x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.81	-0.19
52W Performance	43.3%	85.4%
YTD Performance	78.8%	38.4%
% from 52W High	-4.7%	-14.0%
% from 52W Low	105.6%	110.5%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.76x
FCF Yield (TTM)	-2.0%	-1.8%
Earnings Yield (TTM)	-11.8%	-3.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-72.0	-97.2
EV/GP/RG	N/A	N/A
Ticker research	View NVAX research	View PVLA research

Valuation

P/S Ratio

NVAX

5.07x

PVLA

46.64x

EV/FCF

NVAX

-51.40x

PVLA

-49.96x

Growth & revenue

Revenue Growth TTM

NVAX

-61.6%

PVLA

-97.2%

Forward Revenue Growth

PVLA

287.4%

NVAX

-25.1%

Profitability & performance

Gross Margin

NVAX

79.2%

PVLA

0.0%

ROE

NVAX

283.1%

PVLA

-4784.0%

FCF Yield %

PVLA

-1.8%

NVAX

-2.0%

52-Week Performance

PVLA

85.4%

NVAX

43.3%

Detailed metrics comparison

NVAX

Novavax Inc

PVLA

Palvella Therapeutics Inc

Market Cap

NVAX$2.10B

PVLA$1.99B

Enterprise Value

NVAX$2.20B

PVLA$1.82B

Price

NVAX$12.75

PVLA$138.77

P/E Ratio

NVAXN/A

PVLAN/A

P/S Ratio

NVAX5.07x

PVLA46.64x

EV/Sales

NVAX5.32x

PVLA0.00x

EV/EBITDA

NVAX4.05x

PVLA0.00x

P/B Ratio

NVAX45.86x

PVLA8.80x

P/FCF Ratio

NVAXN/A

PVLAN/A

EV/FCF

NVAX-51.40x

PVLA-49.96x

PEG Ratio

NVAXN/A

PVLAN/A

Forward P/E (NTM)

NVAXN/A

PVLAN/A

Forward P/S (NTM)

NVAX10.28x

PVLAN/A

Revenue (TTM)

NVAX$414M

PVLA$0

Revenue Growth (YoY)

NVAX-61.6%

PVLA-97.2%

Forward Rev Growth

NVAX-25.1%

PVLA287.4%

Gross Margin (TTM)

NVAX79.2%

PVLA0.0%

Operating Margin (TTM)

NVAX0.0%

PVLA0.0%

EBITDA Margin (TTM)

NVAX-24.0%

PVLA0.0%

Net Margin (TTM)

NVAX-59.9%

PVLA0.0%

FCF Margin (TTM)

NVAX-10.4%

PVLAN/A

Net Income (TTM)

NVAX$-248M

PVLA$-62M

FCF (TTM)

NVAX$-43M

PVLA$-37M

EPS (TTM)

NVAX-$1.51

PVLA-$4.30

ROE (TTM)

NVAX283.1%

PVLA-4784.0%

ROA (TTM)

NVAX-2275.0%

PVLA-3833.0%

ROIC (TTM)

NVAX40.0%

PVLA-4172.0%

Cash

NVAX$191M

PVLA$188M

Debt

NVAX$297M

PVLA$22M

Net Cash/Debt

NVAX$-106M

PVLA$166M

Current Ratio (TTM)

NVAX2.33x

PVLA21.18x

Quick Ratio (TTM)

NVAX2.23x

PVLA21.01x

Debt/Equity (TTM)

NVAX6.07x

PVLA0.10x

Debt/Assets (TTM)

NVAX0.0%

PVLA0.0%

Interest Coverage (TTM)

NVAXN/A

PVLAN/A

Net Debt/EBITDA (TTM)

NVAX0.00x

PVLA0.00x

Beta

NVAX2.81

PVLA-0.19

52W Performance

NVAX43.3%

PVLA85.4%

YTD Performance

NVAX78.8%

PVLA38.4%

% from 52W High

NVAX-4.7%

PVLA-14.0%

% from 52W Low

NVAX105.6%

PVLA110.5%

Asset Turnover (TTM)

NVAX0.38x

PVLA0.76x

FCF Yield (TTM)

NVAX-2.0%

PVLA-1.8%

Earnings Yield (TTM)

NVAX-11.8%

PVLA-3.1%

Dividend Yield (TTM)

NVAXN/A

PVLAN/A

Rule of 40

NVAX-72.0

PVLA-97.2

EV/GP/RG

NVAXN/A

PVLAN/A

Ticker research

View NVAX research View PVLA research

Metric	NVAX Novavax Inc	PVLA Palvella Therapeutics Inc
Market & Valuation
Market Cap	$2.10B	$1.99B
Enterprise Value	$2.20B	$1.82B
Price	$12.75	$138.77
P/E Ratio	N/A	N/A
P/S Ratio	5.07x	46.64x
EV/Sales	5.32x	0.00x
EV/EBITDA	4.05x	0.00x
P/B Ratio	45.86x	8.80x
P/FCF Ratio	N/A	N/A
EV/FCF	-51.40x	-49.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	10.28x	N/A
Revenue & Growth
Revenue (TTM)	$414M	$0
Revenue Growth (YoY)	-61.6%	-97.2%
Forward Rev Growth	-25.1%	287.4%
Profitability
Gross Margin (TTM)	79.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-24.0%	0.0%
Net Margin (TTM)	-59.9%	0.0%
FCF Margin (TTM)	-10.4%	N/A
Net Income (TTM)	$-248M	$-62M
FCF (TTM)	$-43M	$-37M
EPS (TTM)	-$1.51	-$4.30
ROE (TTM)	283.1%	-4784.0%
ROA (TTM)	-2275.0%	-3833.0%
ROIC (TTM)	40.0%	-4172.0%
Financial Health
Cash	$191M	$188M
Debt	$297M	$22M
Net Cash/Debt	$-106M	$166M
Current Ratio (TTM)	2.33x	21.18x
Quick Ratio (TTM)	2.23x	21.01x
Debt/Equity (TTM)	6.07x	0.10x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.81	-0.19
52W Performance	43.3%	85.4%
YTD Performance	78.8%	38.4%
% from 52W High	-4.7%	-14.0%
% from 52W Low	105.6%	110.5%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.76x
FCF Yield (TTM)	-2.0%	-1.8%
Earnings Yield (TTM)	-11.8%	-3.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-72.0	-97.2
EV/GP/RG	N/A	N/A
Ticker research	View NVAX research	View PVLA research